Abstracts tagged "Lupus"

Abstract Number: 2675 • 2013 ACR/ARHP Annual Meeting
Phase 2 Trial On Triptorelin For Ovary Protection In Childhood-Onset Systemic Lupus Erythematosus
Rina Mina¹, Andreas Reiff², Clovis A. Silva³, Patricia Vega Fernandez⁴, Gloria C. Higgins⁵, Lisa F. Imundo⁶, Marisa S. Klein-Gitelman⁷, Calvin Williams⁸, Carol A. Wallace⁹, Nadia E. Aikawa¹⁰, Shannen L. Nelson¹¹, Jun Ying¹², Susan R. Rose¹³ and Hermine Brunner¹⁴, ¹Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Division of Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA, ³Children's Institute, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ⁴Cincinnati Children's Hospital Medica Center, CINCINNATI, OH, ⁵Pediatric Rheumatology Ohio State University, Nationwide Childrens Hosp, Columbus, OH, ⁶Pediatric and Adult Rheumatology Columbia University Medical Center, New York, NY, ⁷Division of Rheumatology, Children's Memorial Hospital, Chicago, IL, ⁸Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, ⁹University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA, ¹⁰Reumatologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ¹¹Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹²Medicine-Internal Medicine-General Medicine, University of Cincinnati, Cincinnati, OH, ¹³Endocrinology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁴PRCSG, Cincinnati, OH
Background/Purpose: Gonadotoxicity is a known side effect of cyclophosphamide (CYC) therapy in childhood-onset systemic lupus erythematosus (cSLE). Gonadotropin releasing hormone (GnRH) agonists, such as triptorelin,…
Abstract Number: 1579 • 2013 ACR/ARHP Annual Meeting
Novel Risk Factors For Thrombotic Thrombocytopenic Purpura In Systemic Lupus Erythematosus patients
Javier Merayo-Chalico¹, Diana Gómez-Martín², Roberta Demichelis-Gómez³, Sandra Rajme-Lopez², Luis Aparicio-Vera² and Jorge Alcocer-Varela², ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico city, Mexico, ³Haematology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico city, Mexico
Background/Purpose: Thrombotic thrombocytopenic purpura (TTP) is an uncommon disease characterized by thrombocytopenia and microangiopathic hemolytic anemia and, in some cases, fever, neurologic and/or renal abnormalities.…
Abstract Number: 582 • 2013 ACR/ARHP Annual Meeting
A Real-World Survey Of Clinical Practice Among Rheumatologists and Nephrologists In The United States Reveals Differences In Care Of Non-Nephritis Systemic Lupus Erythematosus and Lupus Nephritis As Compared With American College Of Rheumatology Treatment Guidelines
Neelufar Mozaffarian¹, Steve Lobosco² and Adam Roughley², ¹AbbVie, North Chicago, IL, ²Adelphi Real World Ltd., Macclesfield, United Kingdom
Background/Purpose: Current pharmacotherapy for systemic lupus erythematosus (SLE) and lupus nephritis (LN) includes combinations of nonsteroidal anti–inflammatory drugs (NSAIDs), antimalarials (AMs), glucocorticoids (GCs), and cytotoxic…
Abstract Number: 2662 • 2013 ACR/ARHP Annual Meeting
Quality Of Care Predicts Disease Outcomes Among Patients With Systemic Lupus Erythematosus
Jinoos Yazdany¹, Laura Trupin¹, Patricia P. Katz¹, Gabriela Schmajuk¹ and Edward H. Yelin², ¹Medicine, University of California, San Francisco, San Francisco, CA, ²Medicine, UC San Francisco, San Francisco, CA
Background/Purpose: Although measures to assess quality of care in systemic lupus erythematosus (SLE) are available, their relationship to long-term disease outcomes is unknown. Using a…
Abstract Number: 1443 • 2013 ACR/ARHP Annual Meeting
Is The Risk Of Tumor Necrosis Factor Inhibitor-Induced Lupus The Same With Monoclonal Antibodies and Soluble Receptor? A Case/Non-Case Study In a Nationwide Pharmacovigilance Database
Guillaume Moulis¹, Agnès Sommet², Maryse Lapeyre-Mestre² and Jean-Louis Montastruc², ¹Toulouse University Hospital, Clinical Pharmacology Department, University of Toulouse, UMR INSERM-UPS 1027, Toulouse, France, ²Department of Clinical Pharmacology, Toulouse University Hospital, INSERM U1027, University of Toulouse, France, Toulouse, France
Background/Purpose: Albeit lupus occurring on each TNFi have been reported, no epidemiological study has been conducted to assess the link between lupus onset and each…
Abstract Number: 589 • 2013 ACR/ARHP Annual Meeting
A Survey Of Physician and Patient Satisfaction With Control Of Systemic Lupus Erythematosus and Lupus Nephritis
Neelufar Mozaffarian¹, Steve Lobosco² and Adam Roughley², ¹AbbVie, North Chicago, IL, ²Adelphi Real World Ltd., Macclesfield, United Kingdom
Background/Purpose: Patient satisfaction with disease control is an important component of overall health and well-being. Current treatment options for systemic lupus erythematosus (SLE) ±lupus nephritis…
Abstract Number: 2654 • 2013 ACR/ARHP Annual Meeting
IgG Antibodies Directed Against Domain I Of ß₂-Glycoprotein I Are Significant Predictors Of Thromboembolic Events In Patients With Antiphospholipid Antibodies. A Prospective Cohort Study
Stephane Zuily¹, Bas de Laat², Francis Guillemin³, Pierre Kaminsky⁴, Hilde Kelchtermans⁵, Roger Albesa⁶, Gary L. Norman⁶, Anne-Christine Rat⁷, Philip de Groot⁸, Thomas Lecompte⁹, Veronique Regnault¹⁰ and Denis Wahl¹, ¹CHU de Nancy, Vascular Medicine Division and Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Nancy, F-54000, France; Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France, Nancy, France, ²Biochemistry, CARIM, Maastricht University, The Netherlands; Clinical Chemistry and Hematology, UMC Utrecht, The Netherlands; Synapse BV, Maastricht, The Netherlands; Sanquin Research, Amsterdam, The Netherlands, Maastricht, Netherlands, ³CHU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France, ⁴Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Orphan disease unit, Nancy, F-54000, France;, Nancy, France, ⁵Biochemistry, CARIM, Maastricht University, The Netherlands; Synapse BV, Maastricht, The Netherlands, Maastricht, Netherlands, ⁶Research, INOVA Diagnostics, San Diego, CA, ⁷Université de Lorraine, Nancy, F-54000, France; Inserm, CIC-EC CIE6, Nancy, F-54000, France; CHU de Nancy, Clinical Epidemiology and Evaluation Department, Nancy, F-54000, France; CHU de Nancy, Rheumatology department, Nancy, France, ⁸Clinical Chemistry and Hematology, UMC Utrecht, The Netherlands, Utrecht, Netherlands, ⁹Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Haematology Laboratory, Nancy, F-54000, France; Division of Haematology, HUG, Geneva, Switzerland (current address), Geneva, Switzerland, ¹⁰Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Contrat d’interface, Nancy, F-54000, France, Nancy, France
AbstractBackground/Purpose : Our objective was to prospectively determine the prognostic significance of laboratory variables regarding thrombotic events during follow-up, including novel assays IgG antibodies directed…
Abstract Number: 1256 • 2013 ACR/ARHP Annual Meeting
Depression, Anxiety and Suicidal Thoughts In a Cohort Of Pediatric Lupus and Mixed Connective Tissue Disease Patients
Andrea Knight¹, Pamela F. Weiss², Knashawn Morales³ and Ron Keren⁴, ¹Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Emerging data reveals that depression and anxiety disorders are highly prevalent in adult patients with systemic lupus erythematosus (SLE). These disorders are associated with…
Abstract Number: 590 • 2013 ACR/ARHP Annual Meeting
Candidate Urinary Biomarkers May Predict The Future Development Of Renal Functional Loss With Lupus Nephritis In Children and Adults
Khalid Abulaban¹, Brad H. Rovin², Shannen Nelson³, Huijuan Song⁴, Paul Kimmel⁵, John Kusek⁶, Harold Feldman⁷, Vasan Ramachandran⁸, Michael Bennett⁹, Jun Ying¹⁰ and Hermine Brunner¹¹, ¹Pediatric Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Division of Nephrology, Ohio State University Medical Center, Columbus, OH, ³Rheumatology, Cincinnati Children's Hospital, Cincinnati, OH, ⁴Ohio State University Medical Center, Columbus, OH, ⁵DIVISION OF KIDNEY, UROLOGIC, & HEMATOLOGIC DISEASES, NIDDK, National Institutes of Health, Bethesda, MD, ⁶NIDDK, National Institutes of Health, Bethesda, MD, ⁷The University of Pennsylvania, Philadelphia, PA, ⁸Section of Preventive Medicine and Epidemiology, Boston University School of Medicine, Boston, MA, ⁹Nephrology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹⁰Medicine-Internal Medicine-General Medicine, University of Cincinnati, Cincinnati, OH, ¹¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Lupus nephritis(LN) is frequently associated with a poor long-term prognosis. Current non-invasive blood and urine tests do not reliably predict the course of LN.…
Abstract Number: 2557 • 2013 ACR/ARHP Annual Meeting
Fluctuations In sVCAM-1 and Adiponectin Mirror Fluctuations In Disease Activity In Lupus, But Cannot Be Use To Accurately Predict Impending Changes In Disease State
Carolina landolt-Marticorena¹, Stephenie Prokopec², Stacey Morrison³, Heather Reich⁴, James Scholey⁴, Dafna D. Gladman⁵, Murray B. Urowitz⁵, Paul Boutros², Paul R. Fortin⁶ and Joan E. Wither⁷, ¹Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ²Ontario Institute for Cancer Research, Toronto, ON, Canada, ³Div Rheumatology Rm MP-10-304, The Toronto Western Hospital, Toronto, ON, Canada, ⁴Department of Medicine, The Toronto Western Hospital, Toronto, ON, Canada, ⁵Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶University of Laval, Quebec, QC, Canada, ⁷1E420/Div of Rheumatology, Toronto Western Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Previous reports have identified a number of pro-inflammatory cyto/chemokines as candidate activity-specific SLE biomarkers. In our preliminary studies we found that out of a…
Abstract Number: 1261 • 2013 ACR/ARHP Annual Meeting
The Usefulness Of Traditional Neurocognitive Testing and N-Methyl-D-Aspartate Receptor Antibodies In Pediatric Lupus Patients
Natasha M. Ruth¹, Mary C. Kral², Tamara K. Nowling³, Stephanie Slan⁴, Murray H. Passo⁵ and Gary S. Gilkeson⁴, ¹Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, ²Genetics and Developmental Pediatrics, MUSC, Charleston, SC, ³Medicine/Rheumatology, Medical University of South Carolina and Ralph H. Johnson VA Medical Center, Charleston, SC, ⁴Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁵Pediatrics, Medical University of South Carolina, Charleston, SC
Background/Purpose: In order to identify lupus patients at risk for CNS disease, and specifically, cognitive dysfunction, the ACR recommended a standard battery of tests for…
Abstract Number: 600 • 2013 ACR/ARHP Annual Meeting
Factors Associated With Long-Term Renal Function Deterioration In Lupus Nephritis Treated Initially With Combined Prednisolone and Mycophenolate Mofetil (MMF) Or Tacrolimus (Tac)
Chi Chiu Mok¹, Chi Hung To¹, King Yee Ying², Cheuk-Wan Yim³ and Woon Leung Ng⁴, ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Department of Medicine, Princess Margaret Hospital, Hong Kong, Hong Kong, ³Dept of Medicine, United Christian Hospital, Hong Kong, Hong Kong, ⁴Medicine, United Christian Hospital, Hong Kong, Hong Kong
Background/Purpose: To study the risk factors for renal function decline in patients with lupus nephritis treated initially with combined steroid and MMF or Tac.Methods: Data…
Abstract Number: 2539 • 2013 ACR/ARHP Annual Meeting
The Reliability Of a Novel Automated System For ANA Immunofluorescence Analysis In Daily Clinical Practice
Mohammed Alsuwaidi¹, Margit Dollinger¹, Martin Fleck^1,2 and Boris P. Ehrenstein¹, ¹Rheumatology & Clinical Immunology, Asklepios Clinic Bad Abbach, Bad Abbach, Germany, ²Internal Medicine I, University Medical Center of Regensburg, Regensburg, Germany
Background/Purpose: Recently, automated interpretation (AI) systems for anti-nuclear antibody (ANA) analysis have been introduced based on assessment of indirect immunofluorescence (IIF) patterns. However, the reliability…
Abstract Number: 1063 • 2013 ACR/ARHP Annual Meeting
The Influence Of Socioeconomic and Race In Damage Score In Patients With Systemic Lupus Erythematosus
Roberto Teixeira¹, Eduardo F. Borba², Georges Christopoulos Sr.³ and Emilia Sato⁴, ¹UNIVERSIDADE FEDERAL DE SÃO PAULO, SAO PAULO, Brazil, ²Rheumatology Division; University of São Paulo, São Paulo, Brazil, ³SANTA CASA DE MISERICORDIA DE MACEIO, MACEIO, Brazil, ⁴Medicina, Universidade Federal de São Paulo, São Paulo, Brazil
Background/Purpose: The association between socioeconomic status and damage in Systemic lupus erythematosus patients is confounded by the influence of race in various previous studies. The…
Abstract Number: 564 • 2013 ACR/ARHP Annual Meeting
Role of TLR3 and dsRNA Hyper-Responsiveness in the Generation of the Lupus-Like Phenotype of New Zealand Black Congenic Mice
Gillian Minty¹, Nan-Hua Chang², Kieran Manion³, Yuriy Baglaenko¹, Evelyn Pau⁴ and Joan E. Wither⁵, ¹Immunology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ²Genetics and Development, Toronto Western Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³Immunology, University of Toronto, Toronto, ON, Canada, ⁴Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁵1E420/Div of Rheumatology, Toronto Western Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: New Zealand Black (NZB) mice develop a spontaneous lupus-like autoimmune disease, similar to human systemic lupus erythematosus. Genetic mapping studies have linked loci on…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].